Cartesian Therapeutics, Inc.
About Cartesian Therapeutics, Inc.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $400.0K
- Net income
- -$130.3M
- Total assets
- $296.4M
- Market cap
- $171.6M
- Operating margin
- -5127.1%
- Net margin
- -4658.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $2.8M
- Operating expenses
- $146.2M
- Operating income
- -$143.4M
- Income tax
- -$9.2M
- Net income
- -$130.3M
- EPS (basic)
- $-5.02
- EPS (diluted)
- $-5.02
Balance sheet
- Total assets
- $296.4M
- Current assets
- $129.3M
- Total liabilities
- $422.7M
- Current liabilities
- $14.9M
- Shareholders’ equity
- -$126.2M
Cash flow
- Operating cash flow
- -$73.9M
- Investing cash flow
- -$5.5M
- Financing cash flow
- -$8.1M
- Net cash flow
- -$87.4M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $171.6M
- EPS (diluted)
- $-5.02
- Shares outstanding
- 29.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 22, 2016
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $130.3M in FY2025.
- Revenue declined 89% from FY2023 to FY2025.
- Trading 57% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Cartesian Therapeutics, Inc..
Write a review
News about Cartesian Therapeutics, Inc.
News & sentiment via Polygon.io
